Total Payments
$10,035
2024 Payments
$1,731
Companies
21
Transactions
354
Medicare Patients
2,827
Medicare Billing
$1.0M
Payment Breakdown by Category
Food & Beverage$9,059 (90.3%)
Travel$778.30 (7.8%)
Education$197.81 (2.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,059 | 344 | 90.3% |
| Travel and Lodging | $778.30 | 4 | 7.8% |
| Education | $197.81 | 6 | 2.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $2,695 | 125 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,853 | 34 | $0 (2024) |
| ABBVIE INC. | $1,734 | 74 | $0 (2024) |
| UCB, Inc. | $875.11 | 30 | $0 (2024) |
| Genentech USA, Inc. | $511.74 | 24 | $0 (2020) |
| Horizon Therapeutics plc | $511.08 | 5 | $0 (2023) |
| Lilly USA, LLC | $440.41 | 18 | $0 (2023) |
| Celgene Corporation | $233.31 | 2 | $0 (2019) |
| Janssen Biotech, Inc. | $214.75 | 6 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $162.32 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,731 | 77 | Amgen Inc. ($539.95) |
| 2023 | $1,698 | 68 | Amgen Inc. ($543.98) |
| 2022 | $1,593 | 61 | Amgen Inc. ($717.71) |
| 2021 | $1,241 | 54 | Amgen Inc. ($336.19) |
| 2020 | $661.93 | 31 | Amgen Inc. ($214.19) |
| 2019 | $1,074 | 21 | Novartis Pharmaceuticals Corporation ($287.89) |
| 2018 | $1,756 | 29 | Novartis Pharmaceuticals Corporation ($1,009) |
| 2017 | $279.98 | 13 | Genentech USA, Inc. ($171.44) |
All Payment Transactions
354 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: Inflammation | ||||||
| 12/16/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $20.02 | General |
| Category: Inflammation | ||||||
| 12/13/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $26.85 | General |
| Category: Immunology | ||||||
| 12/13/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $18.57 | General |
| Category: Inflammation | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: Immunology | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.58 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $30.99 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $25.27 | General |
| Category: Immunology | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $32.76 | General |
| Category: Dermatology | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $23.91 | General |
| Category: Immunology | ||||||
| 11/18/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/14/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $19.31 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $25.77 | General |
| Category: Inflammation | ||||||
| 11/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $22.55 | General |
| Category: Immunology | ||||||
| 11/11/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $7.81 | General |
| Category: Inflammation | ||||||
| 11/08/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: Inflammation | ||||||
| 11/06/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $33.26 | General |
| Category: Immunology | ||||||
| 10/31/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: Inflammation | ||||||
| 10/29/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $38.21 | General |
| Category: Rheumatology | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: Dermatology | ||||||
| 10/18/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: Inflammation | ||||||
| 10/08/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: IMMUNOLOGY | ||||||
| 10/02/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: IMMUNOLOGY | ||||||
| 09/24/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: Inflammation | ||||||
| 09/18/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $23.73 | General |
| Category: Bone Health | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 683 | 13,890 | $1.2M | $205,260 |
| 2022 | 14 | 698 | 13,359 | $1.2M | $209,070 |
| 2021 | 14 | 707 | 17,812 | $1.6M | $349,818 |
| 2020 | 17 | 739 | 13,495 | $1.2M | $253,775 |
Total Patients
2,827
Total Services
58,556
Medicare Billing
$1.0M
Procedure Codes
58
All Medicare Procedures & Services
58 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 15 | 10,000 | $690,000 | $105,387 | 15.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 25 | 2,520 | $103,320 | $46,672 | 45.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 141 | 229 | $127,095 | $20,674 | 16.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 150 | 234 | $89,388 | $12,728 | 14.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 79 | 149 | $46,339 | $6,595 | 14.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 19 | 47 | $31,913 | $4,202 | 13.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $11,856 | $1,941 | 16.4% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 56 | 280 | $81,480 | $1,712 | 2.1% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 19 | 29 | $12,008 | $1,605 | 13.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 13 | 74 | $11,026 | $1,544 | 14.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 100 | 219 | $1,314 | $1,288 | 98.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 30 | 49 | $2,450 | $498.64 | 20.4% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 20 | 44 | $1,804 | $414.90 | 23.0% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 21 | 10,350 | $714,150 | $121,475 | 17.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 19 | 1,680 | $68,880 | $28,859 | 41.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 161 | 284 | $138,954 | $23,426 | 16.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 149 | 243 | $84,030 | $15,777 | 18.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 77 | 153 | $47,583 | $6,817 | 14.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 21 | 52 | $35,308 | $5,117 | 14.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 20 | 20 | $13,106 | $2,326 | 17.7% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 18 | 32 | $14,220 | $1,925 | 13.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 13 | 59 | $8,791 | $1,219 | 13.9% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2022 | 47 | 235 | $68,385 | $1,031 | 1.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 93 | 136 | $816.00 | $400.59 | 49.1% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2022 | 22 | 42 | $1,722 | $361.05 | 21.0% |
About Dr. Robert Trapp, MD
Dr. Robert Trapp, MD is a Rheumatology healthcare provider based in Springfield, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1841363751.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Trapp, MD has received a total of $10,035 in payments from pharmaceutical and medical device companies, with $1,731 received in 2024. These payments were reported across 354 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($9,059).
As a Medicare-enrolled provider, Trapp has provided services to 2,827 Medicare beneficiaries, totaling 58,556 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 58 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Springfield, IL
- Active Since 11/16/2006
- Last Updated 05/19/2020
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1841363751
Products in Payments
- Enbrel (Biological) $2,252
- COSENTYX (Biological) $1,405
- RINVOQ (Biological) $883.35
- Cimzia (Drug) $765.82
- Otezla (Drug) $533.58
- KRYSTEXXA (Biological) $493.04
- TALTZ (Drug) $440.41
- SKYRIZI (Biological) $363.36
- Actemra (Biological) $322.65
- COSENTYX (Drug) $254.88
- TREMFYA (Drug) $212.33
- Rituxan (Biological) $189.09
- HUMIRA (Biological) $187.14
- SAPHNELO (Biological) $162.32
- XELJANZ (Drug) $141.72
- Humira (Biological) $132.93
- SIMPONI ARIA (Biological) $114.39
- Bimzelx (Biological) $109.29
- KRYSTEXXA (Drug) $103.59
- KEVZARA (Drug) $99.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Springfield
Jeffrey Horvath, M.d, M.D
Rheumatology — Payments: $254,024
Rheumatology $254,024
David True, D.o, D.O
Rheumatology — Payments: $227,636
Rheumatology $227,636
Cody Wasner, M.d, M.D
Rheumatology — Payments: $188,601
Rheumatology $188,601
Dr. Jason Guthrie, M.d, M.D
Rheumatology — Payments: $124,946
Rheumatology $124,946
Dr. William Hinz, M.d, M.D
Rheumatology — Payments: $28,770
Rheumatology $28,770
Dr. Mark Stern, M.d, M.D
Rheumatology — Payments: $19,392
Rheumatology $19,392